Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 6.50 ($0.08) and last traded at GBX 6.40 ($0.08), with a volume of 91787 shares trading hands. The stock had previously closed at GBX 6.40 ($0.08).
Allergy Therapeutics Trading Down 3.1 %
The business’s 50 day simple moving average is GBX 5.30 and its 200 day simple moving average is GBX 4.98. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The stock has a market cap of £295.74 million, a P/E ratio of -103.33, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Micron Stock Under $100: Seize the AI-Driven Upside
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- 3 Ways To Invest In Coffee, Other Than Drinking It
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
